EGFR and melanoma: Companion diagnostics associated with favourable drug responses comprised genomic alterations in non-small cell lung cancer (EGFR mutations and ALK rearrangements), breast and gastric cancers (HER2/neu amplification or overexpression), and in melanoma (B-RAF mutation).